“Peptides” covers everything from a copper-peptide serum to an injectable sold online. Meta and Google treat those very differently, and most rejections happen because a brand is reviewed as the riskier kind of business.
This guide sorts peptide businesses into four types, shows what each can and can't run, and lists the triggers that get peptide ad accounts banned.
The four kinds of peptide advertiser
Meta and Google don't have a single “peptide policy.” Your ads are judged under different rules depending on what you sell, so start by knowing which group you're in.
| Type of business | Examples | What platforms review you under |
|---|---|---|
| Cosmetic and topical | Peptide serums, eye creams, GHK-Cu skincare | Standard cosmetic rules |
| Oral supplements | Collagen peptides, peptide blends in capsules or powders | Health and supplement rules |
| Prescription via telehealth | Clinics prescribing semaglutide, tirzepatide or sermorelin | Prescription drug and telehealth rules |
| Injectable “research” peptides | BPC-157, TB-500, CJC-1295, ipamorelin | Unapproved and unsafe substance rules |
The further down this table you sit, the stricter the review. Most problems start when a cosmetic or supplement brand uses language that gets it reviewed as one of the bottom two rows.
Peptide ads on Meta (Facebook and Instagram)
Meta doesn't allow peptides to be advertised as human therapeutics. Ads are rejected when copy or imagery implies human use or a health outcome, and Meta's review also checks the landing page (PeptideAds).
- Cosmetic and supplement peptides can run with appearance and “supports” claims. Since July 2026, ads for dietary, health and weight products must target people 18 and over, and claims that a product cures or heals listed diseases are banned (AuditSocials).
- Prescription peptides fall under Meta's prescription drug policy, which requires certification such as LegitScript before ads can run.
- Injectable research peptides are effectively off-limits for consumer ads. Meta's unsafe substances policy names human growth hormone among its examples and lets Meta decide what else qualifies (Meta).
Peptide Google Ads
Google reviews peptide ads under its Healthcare and medicines policy, including the unapproved substances rule. Google won't promote unapproved pharmaceuticals and supplements “regardless of any claims of legality” (Google Ads).
- Cosmetic and supplement peptides run under normal policies if claims stay cosmetic or within supplement limits (Oney Studio).
- Telehealth and prescription peptides need LegitScript Healthcare Merchant Certification plus Google's own healthcare certification before any ads run in the US (Google Ads).
- Compound names such as BPC-157 or TB-500 in headlines, keywords or Shopping feeds are one of the most common disapproval triggers.
What the FDA's April 2026 peptide change means for ads
On April 15, 2026, the FDA said it would remove 12 peptides, including BPC-157, TB-500 and Melanotan II, from its Category 2 list of substances with significant safety concerns. That does not mean they are approved or legal to sell for human use; their status is still under review (Goodwin). Platform ad rules haven't changed because of it.
Banned vs. approved: a quick reference
| Ad element | Meta | |
|---|---|---|
| Appearance claims on topical peptide skincare (“smoother-looking skin”) | Generally approved | Generally approved |
| “Supports” claims on collagen or peptide supplements | Approved with 18+ targeting | Approved within supplement rules |
| Prescription peptides through a certified telehealth provider | Only with certification | Only with LegitScript + Google certification |
| Compound names (BPC-157, TB-500) in headlines or keywords | High rejection risk | High rejection risk |
| Dosage, injection or “protocol” instructions | Rejected | Rejected |
| Claims to cure or heal a disease | Banned | Banned |
| Growth hormone claims | Banned | Banned |
| “Same as” or “comparable to” FDA-approved drugs for compounded products | Rejected | Rejected |
That last row also draws regulators. In February 2026, the FDA sent warning letters to 30 telehealth companies for claims that compounded GLP-1 drugs were comparable to FDA-approved medicines (Telehealth.org).
The 2026 ban wave: why so many peptide advertisers went dark
2026 has been the harshest year yet for Meta ad account bans. Advertisers reported a surge of sudden bans in the first months of the year, including long-standing accounts that had been considered trusted, and Meta hasn't publicly explained it (Affiliate Valley). By mid-year, restrictions were landing at what one industry source called a record pace (The Keyword).
Peptides were hit hard. We watched several peptide advertisers, and entire agencies serving them, lose their ad accounts. The accounts that went down tended to share one profile: low-level operators, both agencies and brands advertising directly, running on standard or throwaway accounts without the setup, relationships or process to back them.
We're still live, and so are the brands we run. That comes down to three things most peptide advertisers don't have:
- Compliance ad accounts. Accounts built for restricted categories from day one, with clean verification, stable payment history and a consistent review record.
- Relationships at Meta and Google. Direct working relationships, so issues get resolved through the right channels instead of an automated appeal queue.
- Best practices developed in restricted verticals. One positioning across ad, page and checkout, landing pages fixed before creative, no resubmit loops, and steady scaling instead of spend spikes.
If your current setup means rebuilding accounts every few weeks, that's the pattern that took whole businesses down this year.
Why peptide ad accounts get banned
Most peptide bans come from a handful of repeat triggers, not one bad ad.
- Implied human use. Before-and-after photos, body-part close-ups, dosing, and words like healing, fat loss or anti-aging.
- Compound names in the wrong places. Headlines, keywords and product feeds are scanned automatically.
- A landing page that doesn't match the ad. A clean ad pointing to a product page full of claims still gets rejected.
- Inconsistent “research use only” framing. An RUO label only holds if the whole business genuinely sells to researchers. RUO wording on a consumer-facing funnel reads to platforms as evasion, and it doesn't change how regulators view products marketed for personal use.
- Repeated resubmits. Every rejection counts against the account, so changing one word and resubmitting makes things worse.
- New accounts after a ban. Platforms treat this as evading enforcement, which can lead to permanent bans across your business assets.
Pre-launch checklist for peptide ads
Run through this before you launch or relaunch any peptide campaign.
- Know your category. Confirm which of the four types your business is, and that your ads, site and checkout all say the same thing.
- Get certified if you prescribe. LegitScript plus each platform's healthcare certification, before the first ad.
- Audit the landing page first. Remove dosing, disease claims, before-and-afters and anything that implies human use you can't support.
- Keep compound names out of headlines and keywords. Describe the product category in ads and keep technical detail on the page.
- Use claims you can substantiate. Appearance claims for cosmetics, “supports” claims for supplements, nothing about curing or treating.
- Target 18+ on Meta for any health, supplement or weight-related product.
- Fix rejections at the root. Change the ad meaningfully, or fix the page, before you request a review.
- Never open new accounts to get around a ban. Appeal through official channels.
What compliant peptide advertising looks like in practice
The peptide brands still scaling after this year's bans treat compliance as the setup, not an afterthought: one clear positioning across ad, page and checkout, claims they can back up, and an account built to stay active. As one peptide brand we work with put it:
“Transparent got us live, kept us live, and scaled our budget at an ROI that made sense for our business. 10 of 10 would recommend.”
FAQ
Can you advertise peptides on Facebook and Instagram?
It depends on the product. Topical peptide skincare and collagen supplements can run with appearance or “supports” claims, targeting adults 18 and over. Prescription peptides need certification. Injectable research peptides can't be advertised for human use.
Can you run Google Ads for peptides?
Yes for cosmetic and supplement peptides with compliant claims. Telehealth providers need LegitScript Healthcare Merchant Certification plus Google's healthcare certification. Unapproved substances can't be promoted, regardless of claims of legality.
Why was my peptide ad rejected?
Usually because the ad or landing page implies human use or a health outcome: dosing, before-and-afters, healing or fat-loss language, or compound names in headlines. Platforms review the landing page too, so check both.
Does the FDA's April 2026 change mean BPC-157 can be advertised?
No. Removing BPC-157 and 11 other peptides from Category 2 doesn't make them approved or legal to sell for human use, and it doesn't change Meta's or Google's ad rules.
Do I need LegitScript certification to advertise peptides?
If you prescribe or sell prescription peptides, yes, on both Meta and Google. Cosmetic and supplement brands usually don't, but their claims must stay within platform limits.
Why did so many peptide ad accounts get banned in 2026?
Meta tightened enforcement sharply in 2026, and peptide advertisers on standard or throwaway accounts were among the hardest hit, including whole agencies. Advertisers with compliance-built accounts, platform relationships and disciplined best practices were far more likely to stay live.
This article is general information, not legal or regulatory advice. Confirm your products' status with your compliance counsel.
Sources
- Google Ads: Healthcare and medicines policy
- Meta: Drugs and pharmaceuticals policy (covers unsafe substances and supplements)
- AuditSocials: Meta's health and wellness policy rewrite (July 2026)
- PeptideAds: Meta ads compliance for peptides (updated Aug 11, 2026)
- Oney Studio: How to advertise peptides on Google (May 26, 2026)
- Goodwin: FDA's evolving stance on peptide compounding (May 11, 2026)
- Telehealth.org: FDA warns telehealth companies over compounded GLP-1 marketing (Feb 2026)
- Affiliate Valley: Meta's 2026 crackdown and mass bans (Apr 20, 2026)
- The Keyword: Meta ad account ban wave 2026 (Jul 23, 2026)